Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.
Richard G. Margolese, MD, of McGill University discusses the improvement in breast cancer-free interval with anastrozole vs tamoxifen in patients with DCIS undergoing lumpectomy plus radiotherapy (Abstract LBA500).
Claus Garbe, MD, of the University of Tuebingen, discusses the survival of sentinel lymph node biopsy–positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).
John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.
